8-Year-Old Harper to Test Gene Therapy for Rare Disease

Eight-year-old Harper Tanton from Cole Harbour is about to make medical history, and her family finally has hope after years of searching for answers.

Harper has CTNNB1 syndrome, a genetic disorder so rare that fewer than 40 cases exist in all of Canada. The condition prevents her body from producing a protein critical for development, leaving her dependent on a wheelchair with significant developmental and speech delays.

For years, her mother Tara searched endlessly for answers. Harper was initially misdiagnosed with cerebral palsy, but Tara refused to accept it, spending nights "going to the bottom of the internet" to find something that matched her daughter's symptoms.

When genetic testing finally revealed CTNNB1 syndrome, doctors said there was no cure. Major pharmaceutical companies won't invest millions for such a small number of patients.

But halfway around the world in Slovenia, parents were fighting back. Spela Mirosevic and her husband founded the CTNNB1 Foundation after their son Urban was diagnosed in 2021, investing all their savings and rallying other families to fund research.

The foundation developed a gene replacement therapy based on treatments for similar conditions. In December, Mirosevic made an impossible choice: her son became the first human to test the experimental treatment, knowing he could die but also knowing without it, he would continue getting worse.

Eight months later, Urban is walking with support, speaking his first words, and eating some foods on his own.

This fall, Harper will become the fourth child in the clinical trial. If successful, her body should produce normal protein levels within six weeks, unlocking her ability to physically and mentally develop in ways her parents once thought impossible.

The Ripple Effect

The procedure requires Harper and her mother to spend at least six months in Slovenia, costing the family an estimated $300,000 in hospital fees, travel, and accommodation.

Their community immediately rallied. Neighbors organized bottle drives, lobster dinners, and yard sales. Kids handed over allowance money in envelopes.

The response shows what happens when people see a family fighting for their child's future. Every dollar raised represents another person who believes Harper deserves this chance.

Scott Tanton, Harper's father, acknowledges the enormous sacrifice of being separated from his daughter and wife while staying behind with their son David. "We have to do it," he said simply, noting they've carefully weighed the risks against the potential for Harper's transformation.

The foundation's success proves that determined families can accomplish what massive pharmaceutical companies won't attempt. What started as one mother refusing to give up on her son has created a pathway for children around the world.

Harper will need weeks of testing before the actual procedure, followed by regular trips back to Slovenia for assessments. But for the first time since her diagnosis, the Tanton family isn't just managing Harper's condition—they're hoping to cure it.